Jeffrey Eaton Hull

Jeffrey Eaton Hull

Auto-generated profile, based on publicly available information

Jeffrey Eaton Hull

Richmond Vascular Center, Richmond, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
JHJeffrey E. Hull
Jeffrey E. Hull
WJWilliam C. Jennings
William C. Jennings
RCRandy I. Cooper
Randy I. Cooper
UWUmar Waheed
Umar Waheed
MSMatthew E. Schaefer
Matthew E. Schaefer
RNRajeev Narayan
Rajeev Narayan
To evaluate safety and efficacy of arteriovenous fistulas (AVFs) created with a thermal resistance anastomosis device. A prospective single-arm trial at 5 sites enrolled 107 patients. Patients underwent ultrasound (US)-guided anastomosis creation between the proximal radial artery and perforating vein with the Ellipsys Vascular Access System (Avenu Medical, Inc, San Juan Capistrano, California) followed by separate maturation procedures. Primary endpoints were brachial artery flow volume ≥ 500 mL/min and target vein diameter ≥ 4 mm in > 49% of patients and absence of device-related complications at 90 days. AVFs with fused anastomoses were created in 95% (102/107) of patients. Maturation procedures included anastomotic balloon dilation in 72% (77/107), brachial vein embolization in 32% (34/107), cubital vein ligation in 31% (33/107), and surgical transposition in 26% (28/107) of patients. Primary flow and diameter endpoints were achieved in 86.0% (92/107) of patients, exceeding performance goal of 49% (P < .0001). No major adverse events were attributed to the device. Cumulative patency was 91.6%, 89.3%, and 86.7% at 90 days, 180 days, and 360 days. Target dialysis veins were cephalic, basilic, and brachial veins in 74% (73/99), 24% (24/99), and 2% (2/99) of patients. Two-needle dialysis was achieved in 88% (71/81) of patients on hemodialysis at a mean 114.3 days ± 66.2. Functional patency was 98.4%, 98.4%, and 92.3% at 90 days, 180 days, and 360 days. The Ellipsys® Vascular Access System met primary safety and efficacy endpoint goals in the US pivotal trial.

1 March 2017 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
JHJeffrey E. Hull
Jeffrey E. Hull
GEGuillermo Elizondo-Riojas
Guillermo Elizondo-Riojas
WBWendy Bishop
Wendy Bishop
YVYesenia L. Voneida-Reyna
Yesenia L. Voneida-Reyna
To evaluate the safety and efficacy of arteriovenous fistula (AVF) creation with a thermal resistance anastomosis device (TRAD). From January 2014 to March 2015, 26 patients underwent ultrasound (US)-guided percutaneous creation of proximal radial artery-to-perforating vein AVFs with a TRAD that uses heat and pressure to create a fused anastomosis. Primary endpoints were fistula creation, patent fistula by Doppler US, two-needle dialysis at the prescribed rate, and device-related complications. Technical success rate of fistula creation was 88% (23 of 26). Procedure time averaged 18.4 minutes (range, 5-34 min), and 96% of anastomoses (22 of 23) were fused. At 6 weeks, 87% of AVFs (20 of 23) were patent, 61% (14 of 23) had 400-mL/min brachial artery flow, 1 patient was receiving dialysis, 2 fistulae had thrombosed, and 1 patient had died unrelated to the procedure. Eighty percent (16 of 20), 70% (14 of 20), and 60% (12 of 20) of patients were receiving dialysis at 3, 6, and 12 months; 4 patients died, 3 fistulae failed, and one patient was lost to follow-up. Overall, 87% of AVFs (20 of 23) had an additional procedure at a mean of 56 days (range, 0-239 d), including balloon dilation in 43% (n = 10), brachial vein embolization in 26% (n = 6), basilic vein ligation in 17% (n = 4), venous transposition in 30% (n = 7), and valvulotomy in 4% (n = 1). There were no major complications related to the device. Percutaneous AVFs created with a TRAD met the safety endpoints of this study. Midterm follow-up demonstrated intact anastomoses and fistulae suitable for dialysis.

1 January 2009 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JHJeffrey E. Hull
Jeffrey E. Hull
SRScott W. Robertson
Scott W. Robertson

1 July 2013 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JHJeffrey E. Hull
Jeffrey E. Hull
BBBoris V. Balakin
Boris V. Balakin
BKBrad M. Kellerman
Brad M. Kellerman
DWDavid K. Wrolstad
David K. Wrolstad

23 April 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
AHAndrew Holden
Andrew Holden
HHHiroaki Haruguchi
Hiroaki Haruguchi
KSKotaro Suemitsu
Kotaro Suemitsu
NINaoko Isogai
Naoko Isogai
JRJohn Ross
John Ross
RLRobert Lookstein
Robert Lookstein
To present the 12-month outcomes of the IN.PACT AV Access Study, a prospective, single-blind trial enrolling participants with obstructive de novo or restenotic native upper extremity arteriovenous dialysis fistula lesions treated with a drug-coated balloon (DCB) or percutaneous transluminal angioplasty (PTA). After successful high-pressure PTA, participants at 29 international sites were randomized 1:1 to treatment with an IN.PACT AV DCB (n = 170) or standard uncoated PTA (n = 160). Outcomes at 12 months include target lesion primary patency (TLPP), defined as freedom from clinically driven target lesion revascularization or access circuit thrombosis; access circuit primary patency; number of reinterventions; and adverse events involving the access circuit. At 12 months, TLPP was 63.8% (90/141) in the DCB group compared with 43.6% (61/140) in the PTA group (P < .001). The total number of reinterventions required to maintain TLPP through 360 days was 93 in the DCB group and 144 in the PTA group, with a 35.4% reduction in reinterventions when DCB was used. Access circuit thrombosis occurred in 2.9% (4/138) of the participants in the DCB group and in 6.2% (8/129) of those in the PTA group (P = .19). Time to TLPP was assessed using a multivariable analysis to identify the factors associated with loss of patency. The treatment device was the independent predictor with the largest effect, with a hazard ratio of 0.42 (95% confidence interval, 0.29-0.60; P < .001). TLPP was statistically significantly higher with DCBs than with standard PTA at 12 months, demonstrating the sustained and superior effectiveness of this device for the treatment of dysfunctional arteriovenous dialysis fistulae.

1 December 1992 in Radiology
Verified
Journal Article
Closed access
JHJ E Hull
J E Hull
CHC S Hunter
C S Hunter
GLG A Luiken
G A Luiken
Fifty Groshong catheters were placed in 50 patients with use of ultrasound (US) and fluoroscopic guidance in the radiology suite: 49 were placed via the subclavian vein and one was placed via the left internal jugular vein. All (100%) attempts at catheter placement were successful. Imaging guidance affected the placement of catheters in 12 cases (24%), including four patients (8%) in whom vascular access would not have been possible with blinded percutaneous venipuncture or surgical cutdown. After a four-case learning curve period, during which one pneumothorax (2%) and two arterial punctures (4%) occurred, there were no further venipuncture-related complications. One catheter was removed because of infection (2%) and one because of allergic reaction (2%) to the antimicrobial cuff. Four patients with cutaneous infections and one with catheter-related sepsis were successfully treated with antibiotics. Results demonstrate the initial promise of imaging-guided placement of central venous access catheters when performed in the radiology suite.